Table A2.
Parameters | Parameter estimates (RSE %) | |||
---|---|---|---|---|
Deaths at EOT n= 98 | Disability n= 364 | Cognitive impairment n= 89 | Depression n= 183 | |
Baseline hazard | 1.28 × 10−5 | 2.45 × 10−3 | 1.39 × 10−4 | 5.79 × 10−2 |
β0, u year−1 | (18) | (58) | (10) | (27) |
Time | 0.127 | −0.250 | – | −0.385 |
βtime, year−1 | (38) | (20) | (15) | |
Age at study entry | 0.0649 | 0.0257 | 0.075 | – |
βage, year−1 | (10) | (48) | (4) | |
Selegiline | 0.925 | −0.451 | – | −0.466 |
βDP, at 10 mg day−1 | (28) | (35) | (37) | |
Levodopa | – | – | – | |
βLD, at 300 mg day−1 | ||||
Disease status measure | UPDRS | UPDRS | PIGD | UPDRS |
βDS, per unit | 0.0336 | 0.101 | 0.147 | 0.036 |
(10) | (9) | (28) | (18) |
EOT, end of trial; UPDRS, United Parkinson's Disease Rating Scale; PIGD, postural instability gait disorder score.
The death hazard model h, as a function of time is:
h(time) =β0 * exp(βtime * time +βage * Age0+βDP * DP +βLD * LD +βDS * status(time))
Age0 is age at study entry; DP is 1 when selegiline is used, LD is 1 when levodopa is used otherwise DP and LD are zero; Status(time) is the predicted disease status e.g. UPDRS, at time since study entry.